Page 10 - Cipla

Delhi HC restrains Cipla from using Gluco-C or Gluco-D trademarks

Zydus argued that Cipla started branding its Glucose product under Gluco C ++ and Gluco D ++, in order to create confusion in the minds of customers

Stocks to watch: Coal India, Mankind Pharma, EID Parry, India Pesticides

Stocks to watch on June 1, 2023: From Coal India to Mankind Pharma, here are top stocks to watch in Thursday's trading session

Cipla's Q4 net profit up 45% at Rs 526 cr on account of robust sales

Drug major Cipla on Friday said its consolidated net profit increased by 45 per cent to Rs 526 crore for the fourth quarter ended March 31, 2023, driven by robust sales across the domestic business and US market. The Mumbai-based company had reported a net profit of Rs 362 crore for the January-March quarter of 2021-22 fiscal. Total revenue from operations rose to Rs 5,739 crore for the fourth quarter as compared with Rs 5,260 crore in the year-ago period, Cipla said in a regulatory filing. For the year ended March 31, 2023, the drug maker reported a consolidated net profit of Rs 2,802 crore as against Rs 2,517 crore in FY22. Total revenue rose to Rs 22,753 crore last fiscal as against Rs 21,763 crore in 2021-22 fiscal. "In FY23, we recorded the highest ever revenue with EBITDA crossing Rs 5,000 crore for the first time. Our One-India business continued the double-digit trajectory growing at 13 per cent ex-Covid during the year led by branded prescription and sustained growth acros

Results preview: India business to put a spring in pharma's step

Hospitals to recover from sluggish Q3; diagnostics' growth rate at pre-Covid levels

Stocks to watch: JSW Steel, Cipla, Zydus Life, Kaveri Seed, Kalpataru Power

Stocks to watch today: From Cipla to Zydus Lifesciences, here are top stocks to watch in Tuesday's trading session

Cipla inks licensing pact with Novartis to manufacture, mkt diabetes drug

Drug major Cipla on Monday said it has inked a licensing pact with Novartis Pharma AG to manufacture and market Galvus range, used in the treatment of type 2 diabetes, from January 1, 2026. The Mumbai-based company has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) to manufacture and market Galvus and Galvus combination brands, it said in a regulatory filing. "This deal is expected to further bolster Cipla's position in India as one of the top players in the diabetes category," it added. The agreement is subject to satisfaction of certain conditions precedent, the drug firm said. Galvus is one of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space and amongst the prominent brands in the oral diabetic medication category, the drug firm stated. On Monday, shares of Cipla ended 1.02 per cent up at Rs 901.85 apiece on the BSE.

Sensex falls for 5th straight day, ends 344 pts down; Nifty breaks 17,000

CLOSING BELL: The Nifty 50 ended below the 17,000-mark for the first time since October 11, 2022. The NSE benchmark has now shed 630 points in the last five trading sessions.

Amazon Web Services served Rs 549 crore income tax demand notice: Report

AWS: The income tax department has reportedly raised the demand for Rs 190.85 crore tax for 2014-15 and Rs 358.27 crore for 2016-17 by invoking Section 147 of the Income-tax Act

RIL, Mphasis: 45 stocks hit fresh 52-week lows; charts show more pain ahead

The heavy-weight Reliance Industries has broken critical support of Rs 2,300, raising concerns about the future drawdown. In addition, the formation reveals a "Descending Triangle" violation

Stocks to watch: Cipla, Axis Bank, PNC Infratech, RailTel, Glenmark Pharma

Stocks to watch today: From Cipla to Axis Bank, here are top stocks to watch out in Wednesday's trading session

Cipla inks pact with Africa Capitalworks to sell 51% stake in Uganda unit

Drug major Cipla on Tuesday said it has inked a pact with Africa Capitalworks to sell a 51.18 per cent stake in Uganda-based Cipla Quality Chemical Industries Ltd. The company and its wholly-owned subsidiaries, Cipla (EU) Ltd and Mauritius-based Meditab Holdings Ltd, have entered into a share purchase agreement with Africa Capitalworks on March 14, Cipla said in a regulatory filing. Subsequent to the sale, Cipla Quality Chemical Industries (CQCIL) will cease to be a subsidiary of the company, it added. Consideration to be received by Cipla (EU) Ltd and Meditab Holdings Limited shall be in the range of USD 25-30 million, Cipla noted. The proposed sale is expected to be completed by May 31, 2023, it added. Africa Capitalworks is a wholly owned subsidiary of Africa Capitalworks Holdings (ACW), an investment management company incorporated in Mauritius. ACW is engaged in providing permanent equity capital and complementary skills to mid-market companies across Sub-Saharan Africa.

NTPC, PFC: 5 F&O stocks see long OI build-up; Here's how to trade in them

Build-up of long OI in general indicates that traders are expecting the price of the underlying stock or index to gain in the near-term.

TMS Ep381: SC on Adani-Hindenburg, employment data, Cipla stocks, and more

What next in the Adani-Hindenburg saga? What do India's employment numbers imply? What do USFDA observations mean for Cipla? What is the New START Treaty?

Analysts turn cautious on Cipla as US FDA action delays key US launches

Analysts believe that some of the recent observations from the US FDA are critical in nature and could lead to a potential Official Action Indicated (OAI) classification for the Indore plant

Cipla falls 4%, nears 52-week low on concerns of product launch delay in US

In the past seven trading days, the stock has dipped 11% after the United States Food and Drug Administration issued Form 483 with 8 observations for the company's Pithampur manufacturing facilities

Nifty Pharma dips to 7-mth low; bears may gain control if breaks 52-wk low

Barring Sun Pharmaceutical Industries, which is anticipated to rally up to 10 per cent; other stocks indicate weak bias, as per technical charts

Cipla shares fall over 6% after its unit gets 8 observations from USFDA

Shares of Cipla on Monday ended over 6 per cent lower after the company received 'Form 483' with eight observations for its Pithampur-based manufacturing facility. The stock declined 6.02 per cent to settle at Rs 964.05 apiece on the BSE. During the day, it tumbled 6.78 per cent to Rs 956.20. On the NSE, it tanked 6.11 per cent to end at Rs 963 per share. In volume terms, 2.38 lakh shares were traded on the BSE and over 58.29 lakh shares on the NSE during the day. The US Food and Drug Administration (USFDA) conducted a current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility from February 6-17, the Mumbai-based drug firm said in a regulatory filing on Saturday. On conclusion of the inspection, the company has received eight inspectional observations in Form 483, it added. The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time, it said. As per USFDA, Form 483 is issued to a firm's managemen

Cipla dips 7% after Pithampur unit receives 8 USFDA observations

The company said it will work closely with the USFDA and is committed to address these comprehensively within stipulated time.

Stocks to watch: HUL, United Breweries, Motherson, Sun Pharma, Paytm, Cipla

Stocks to watch: Samvardhana Motherson announced it is buying SAS Autosystemtechnik (SAS), which manufactures auto cockpit modules, from French company Faurecia for Rs 4,790 crore

Income tax department conducts survey action against drug major Cipla

The Income Tax Department has carried out a survey action against drug major Cipla, sources said on Tuesday. The department is conducting the surprise action to check the balance sheets and other business documents of the Mumbai headquartered company as part of an alleged tax evasion investigation, they said. As part of a survey, the Income Tax Department only covers the business premises of a company and does not raid the residences and other locations of its promoters or directors. The company had last week reported, in a regulatory filing, a seven per cent increase in its consolidated net profit at Rs 808 crore in the third quarter ending December 2022, aided by robust sales in the US market.